Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iveric Bio Inc (NQ: ISEE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iveric Bio Inc

< Previous 1 2 3 4 5 6 Next >
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
The Latest Analyst Ratings for IVERIC bio
Via Benzinga
Analyst Ratings for IVERIC bio
Via Benzinga
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? 
Via News Direct
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
IVERIC Bio (ISEE) Q4 2022 Earnings Call Transcript
ISEE earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. 
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
Via Benzinga
IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Eastside Distilling Shares Are Trading Lower By Over 25%; Here Are 20 Stocks Moving Premarket
Gainers Hitek Global Inc. (NASDAQ: HKIT) jumped 25.5% to $6.98 in pre-market trading after gaining 11% on Friday. Hitek Global priced its initial public offering of 3,200,000 ordinary shares at a price... 
Via Benzinga
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Nogin, Inc. (NASDAQ: NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 101% to $14.24 after climbing 50% on Friday. 
Via Benzinga
Apellis Pharmaceuticals, VirTra And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
IVERIC bio's Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.